Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.49 |
| ▸ | KDM6B | O15054 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20511499 | 0.85 | KDM4C (0.46) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL30425929 | 0.85 | KDM4C (0.46) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4544606 | 0.85 | KDM4C (0.53) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL1656950 | 0.84 | POLB (0.52) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL1327240 | 0.83 | SIRT3 (0.59) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL11504517 | 0.82 | KDM4C (0.50) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL3077352 | 0.81 | CA12 (0.43) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL4755993 | 0.80 | SLC22A12 (0.48) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL16611699 | 0.80 | HSD17B10 (0.49) | KDM4CKDM6BTDP1ALDH1A1L3MBTL1 | |
| SCHEMBL18757802 | 0.80 | CA12 (0.44) | KDM4CTDP1ALDH1A1L3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4493743-A1 | GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE | Université de Franche-Comté (FR) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023174871-A1 | GOLD ELECTROPLATING SOLUTION AND ITS USE FOR ELECTRODEPOSITING GOLD WITH AN AGED APPEARANCE | Université de Franche-Comté (FR) | 2023-09-21 | — | — | WO | disclosed |
| WO-2016168510-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2010005384-A1 | KETONE PYRIDINE ANALOGUES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ASTRAZENECA AB (SE) | 2010-01-14 | — | — | WO | disclosed |
| EP-2111400-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | AstraZeneca AB (SE) | 2009-10-28 | — | — | EP | disclosed |
| US-7422793-B2 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-09-09 | — | — | US | disclosed |
| US-7407711-B2 | Non-toxic corrosion-protection conversion coats based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-08-05 | — | — | US | disclosed |
| WO-2008085117-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-7294211-B2 | Non-toxic corrosion-protection conversion coats based on cobalt | UNIVERSITY OF DAYTON (US) | 2007-11-13 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| US-20030234063-A1 | Non-toxic corrosion-protection conversion coats based on cobalt | DAYTON, UNIVERSITY OF | 2003-12-25 | — | — | US | disclosed |
| US-20030230363-A1 | Non-toxic corrosion-protection rinses and seals based on cobalt | UNIVERSITY OF DAYTON | 2003-12-18 | — | — | US | disclosed |
| WO-2003060192-A1 | NON-TOXIC CORROSION-PROTECTION RINSES AND SEALS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060191-A2 | NON-TOXIC CORROSION-PROTECTION CONVERSION COATINGES ABSED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003060019-A1 | NON-TOXIC CORROSION PROTECTION PIGMENTS BASED ON COBALT | UNIVERSITY OF DAYTON (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20020035127-A1 | Phenylalanine derivatives | CELLTECH THERAPEUTIS, LIMITED | 2002-03-21 | — | — | US | disclosed |
| US-6329372-B1 | HETEROCYCLIC AMIDE COMPOUNDS ARE ABLE TO INHIBIT THE BINDING OF ALPHA4 INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS. | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-12-11 | — | — | US | disclosed |
| EP-0741707-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1996-11-13 | — | — | EP | disclosed |
| WO-1995020578-A1 | SUBSTITUTED AROMATIC COMPOUNDS AS c.AMP PHOSPHODIESTERASE- AND TNF-INHIBITORS | RHONE-POULENC RORER LIMITED (GB) | 1995-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035127-A1 | Phenylalanine derivatives | PAH, VCAM1, IL4I1 | KDM4C 860/4885KDM6B 1809/4885TDP1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.